CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR ), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen [email protected] 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg [email protected] -- Financial Tables Follow – SOURCE Citius Oncology, Inc.OK folks, give me a clue, what day is it? Friday, apparently, as I consider the A-League round, Saturday if you have a newspaper in front of you. Adelaide will have played the Western Sydney Wanderers and Perth will have hosted Macarthur last night and today there will be three fixtures for our consumption. Login or signup to continue reading The Jets, having had last weekend off, are in New Zealand taking on Wellington at 3pm our time, the Mariners host Auckland just down the freeway later in the afternoon, and Sydney FC host Melbourne Victory in the "highlight" fixture as the sun goes down. The improving Western United host a struggling Brisbane Roar on Sunday afternoon to complete the weekend fixtures, before several midweek fixtures on New Year's Eve and New Year's Day herald the arrival of January, midweek match month. The Jets have played the least number of games of any club, one less than most, two fewer than a small number, and have a bit of ground to make up after a difficult early-round schedule. I know without checking that in an early column I suggested their start - two home games before the turn of the year, three in the first 10 games and two byes in among that run - could make accumulating points early in the campaign difficult and leave the Jets chasing the pack. Unsurprisingly, that seems to be the case. I know that when I sit down to get an overview of the competition, I always find myself thinking, 'Geez, this is a crunch game for the Jets'. Certainly, accumulating a few more points would have eased those concerns, but so might have a couple of extra games, particularly home games by this juncture. Instead we introduce a little scoreboard pressure to an already difficult run of games. It's my job to point that out, it's the players job to ignore it as best they can. This weekend, for example, could conceivably leave the Jets quite glaringly adrift of the current top six. Wellington away is no easy game and it's not too hard to imagine they could leave empty-handed. On the same weekend it's not unreasonable to imagine that Macarthur could win in Perth and Western United win at home against the Roar. Fair assumption? If Melbourne City then gather a point (or more) at the Mariners on Tuesday evening, the three sides at the lower end of the top six will have 15 points or more, nine ahead of Newcastle with approximately a third of the season done. Consider then that Sydney FC, the Wanderers and Wellington are not in that top six but ahead of the Jets, and you begin to comprehend that the road is long. If that's not scoreboard pressure, I'm not sure what is. What I am sure of is that the Jets need some points soon, starting with some this afternoon in Wellington. Last season's surprise packet have struggled a little to maintain the same high standards and consistency to this point, and don't have the confidence and momentum that was a feature of last season's title challenge. Funnily enough, on the back of an excellent start to that campaign. They are, it seems, a little more vulnerable, and I'm sure the Jets will have a plan, and the mobility and freshness to challenge hard. They need to. Next week, back at home at McDonald Jones Stadium, they host Sydney FC. It won't be easy, in fact I'm sure I will rate it as "crucial". New Year, some things never change. But hey, let's hope for some excitement, success and progress. It's not out of reach. Happy New Year. DAILY Today's top stories curated by our news team. Also includes evening update. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Get the latest property and development news here. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. WEEKLY Follow the Newcastle Knights in the NRL? Don't miss your weekly Knights update. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily!
291 jili slot
。
Same glitz and glamour for the Las Vegas Grand Prix, and perhaps another Verstappen championshipMan City blows 3-goal lead and gets booed by fans in draw with Feyenoord in Champions League
How co-writing a book threatened the Carters' marriage NEW YORK (AP) — No ex-president had a more prolific and diverse publishing career than Jimmy Carter . His more than two dozen books included nonfiction, poetry, fiction, religious meditations and a children’s story. Canadian Press Dec 29, 2024 2:19 PM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message This combination of book cover images shows some of the many books authored by President Jimmy Carter, top row from left, "An Hour Before Daylight: Memories of a Rural Boyhood," "Christmas in Plains: Memories," "The Nobel Peace Prize Lecture," "The Hornet's Nest: A Novel of the Revolutionary War," "Sharing Good Times," "Our Endangered Values: America's Moral Crisis," and "Palestine: Peace Not Apartheid," bottom row from left, "Beyond the White House," "A Remarkable Mother," "We Can Have Peace in the Holy Land: A Plan That Will Work," "White House Diary" (FSG), "A Call to Action: Women, Religion, Violence, and Power," "A Full Life: Reflections at Ninety," and "Faith: A Journey for All." (Simon & Schuster/FSG via AP) NEW YORK (AP) — No ex-president had a more prolific and diverse publishing career than Jimmy Carter . His more than two dozen books included nonfiction, poetry, fiction, religious meditations and a children’s story. His memoir “An Hour Before Daylight” was a Pulitzer Prize finalist in 2002, while his 2006 best-seller “Palestine: Peace Not Apartheid” stirred a fierce debate by likening Israel’s policies in the West Bank to the brutal South African system of racial segregation. And just before his 100th birthday, the Dayton Literary Peace Prize Foundation honored him with a lifetime achievement award for how he wielded "the power of the written word to foster peace, social justice, and global understanding.” In one recent work, “A Full Life,” Carter observed that he “enjoyed writing” and that his books “provided a much-needed source of income.” But some projects were easier than others. “Everything to Gain,” a 1987 collaboration with his wife, Rosalynn, turned into the “worst threat we ever experienced in our marriage,” an intractable standoff for the facilitator of the Camp David accords and winner of the Nobel Peace Prize. According to Carter, Rosalynn was a meticulous author who considered “the resulting sentences as though they have come down from Mount Sinai, carved into stone.” Their memories differed on various events and they fell into “constant arguments.” They were ready to abandon the book and return the advance, until their editor persuaded them to simply divide any disputed passages between them. “In the book, each of these paragraphs is identified by a ‘J’ or an ‘R,’ and our marriage survived,” he wrote. Here is a partial list of books by Carter: “Keeping Faith: Memoirs of a President” “The Blood of Abraham: Insights into the Middle East” (With Rosalynn Carter) “Everything to Gain: Making the Most of the Rest of Your Life” “An Outdoor Journal: Adventures and Reflections” “Turning Point: A Candidate, a State, and a Nation Come of Age” “Always a Reckoning, and Other Poems” (With daughter Amy Carter) “The Little Baby Snoogle-Fleejer” “Living Faith” “The Virtues of Aging” “An Hour Before Daylight: Memories of a Rural Boyhood” “Christmas in Plains: Memories” “The Hornet’s Nest: A Novel of the Revolutionary War” “Our Endangered Values: America’s Moral Crisis” “Faith & Freedom: The Christian Challenge for the World” “Palestine: Peace Not Apartheid” “A Remarkable Mother” “Beyond the White House” “We Can Have Peace in the Holy Land: A Plan That Will Work” “White House Diary” “NIV Lessons from Life Bible: Personal Reflections with Jimmy Carter” “A Call to Action: Women, Religion, Violence, and Power” “A Full Life: Reflections at Ninety” The Associated Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message More Entertainment News Charles Shyer, ‘Father of the Bride’ and ‘Baby Boom’ filmmaker, dies at 83 Dec 29, 2024 2:26 PM 'Sonic 3' and 'Mufasa' battle for No. 1 at the holiday box office Dec 29, 2024 9:55 AM 'Sonic 3' and 'Mufasa' battle for No. 1 at the holiday box office Dec 29, 2024 9:02 AM Featured Flyer
Repealing no-fault divorce has so far stalled across the US. Some worry that'll change